GLP-1 evidence by condition.
17 condition profiles, each anchored in the registration trial that produced the evidence (FLOW for kidney, STEP-HFpEF and SUMMIT for heart failure, ESSENCE for MASH, SURMOUNT-OSA for sleep apnea, SELECT for cardiovascular). Each profile gives you the trial, the qualifying clinical picture, the questions to ask your prescriber, and a direct link to the matching PA letter template. Editor-written from public trial data and FDA labeling. We do not yet have a credentialed medical reviewer (actively recruiting); this content is editorial, not medical advice.
Single-condition evidence
Trial-anchored profiles for each major qualifying condition. Start here when one indication dominates the clinical picture.
Stacked comorbidity cases
When two or three qualifying conditions converge in one clinical scenario, the PA case stacks. These pages address the trifecta and trifecta-adjacent cases where the trial evidence overlaps across indications.
How to read these pages
Each condition page is built around a single named trial that produced the evidence base. We name the trial by acronym (FLOW, ESSENCE, SURMOUNT-OSA, etc.), cite the published source (most often NEJM or Lancet), and quote the headline result with the hazard ratio and confidence interval. We then summarize the enrollment criteria so you can see whether the trial applies to your clinical picture.
At the bottom of each page we link to the matching PA letter template in our prior authorization letter library so you can take the next step. If you have already been denied, the appeal letter library has direct rebuttals to the most common denial reasons.
What this is and what it is not
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.
